Navigation Links
MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
Date:10/23/2008

GAITHERSBURG, Md., Oct. 23 /PRNewswire/ -- MedImmune today announced that researchers will present eight posters from its inflammatory disease program at the Annual Meeting of the American College of Rheumatology, from October 24 to 29, 2008 at the Moscone Center in San Francisco, California.

"MedImmune is working on a number of potential solutions for patients struggling with systemic autoimmune rheumatic diseases," said Barbara White, M.D., vice president, clinical development, respiratory, inflammation, and autoimmunity. "We are pleased to share promising basic research and translational science data relevant to the development of new treatments for diseases such as lupus, rheumatoid arthritis, and myositis"

MedImmune programs that will be discussed include:

-- MEDI-545 - MEDI-545 is a monoclonal antibody (MAb) targeting

interferon-alpha, which regulates processes involved in autoimmune

diseases. MedImmune has launched a broad development program with this

molecule to assess its potential to treat or prevent a variety of

immunological disorders. Currently, MedImmune is conducting a phase 2a

trial in patients with systemic lupus erythematosus (SLE) and a phase 1b

study in patients with active dermatomyositis and polymyositis. The

company has also conducted clinical trials in psoriasis with MEDI-545.

-- CAM-3001 - CAM-3001 is a MAb with potential to help patients with

rheumatoid arthritis. The antibody targets the alpha sub-unit of the

granulocyte-macrophage colony stimulating factor receptor (GM-CSFR).

CAM-3001 is a phase 1 clinical stage program.

-- ICOS - ICOS (Inducible costimulator) is a receptor on activated T-cells

that plays a central role in humoral immunity. Elevated levels of ICOS

are present in patients with autoimmune diseases and effector cytokines

have been shown to correlate with increased levels of this protein.

MedImmune has a preclinical program studying the over-expression of ICOS

in several autoimmune diseases.

-- CXCL13 - CXCL13 is a molecule that recruits B cells into inflammatory

cell aggregates called follicles. In patients with rheumatoid arthritis

the levels of CXCL13 are elevated within the inflamed joints thus

encouraging B cells to accumulate and interact with a range of cells,

such as T cells, within the joint promoting the generation of new

inflammatory follicles and contributing to the disease process.

MedImmune has a preclinical program investigating antibodies that target CXCL13 which may have the potential to prevent the generation of these inflammatory follicles within the rheumatic joint.

The schedule for MedImmune's eight research posters to be presented at the meeting, starting on Sunday October 26, is as follows:

-- ICOS as a potential regulator in inclusion body myositis and

dermatomyositis - Chris Morehouse, M.Sc., Sunday, October 26 from 9:00

a.m. - 11:00 a.m. in Hall A, Abstract: 46

-- Internalization of the antibody (CAM-3001) following monocyte cell

surface binding to the GM-CSFR alpha chain - Brandon Higgs, Ph.D.,

Sunday, October 26 from 9:00 a.m. - 11:00 a.m. in Hall A, Abstract: 35

-- Neutralization of CXCL13 impacts B-cell trafficking and reduces severity

of established experimental arthritis - Matthew Sleeman, Ph.D., Monday,

October 27 from 9:00 a.m. - 11:00 a.m. in Hall A, Abstract: 771

-- IFN-alpha/beta as a therapeutic target in systemic lupus erythematosus,

myositis, and rheumatoid arthritis: a transcript profiling analysis of

whole blood from multiple autoimmune diseases - Brandon Higgs, Ph.D.,

Tuesday, October 28 from 9:00 a.m. - 11:00 a.m. in Hall A, Abstract:

1346

-- Neutralizing IFN-alpha in SLE affects GMCSF, TNF-alpha, IL-10, IL1-beta

and BAFF signaling pathways - Brandon Higgs, Ph.D., Tuesday, October 28

from 9:00 a.m. - 11:00 a.m. in Hall A, Abstract: 1340

-- Memory T lymphocytes expressing the inducible costimulator (icos) are

required to maintain the secondary lymphoid tissue architecture in non

human primates - Gianluca Carlesso, Ph.D., Tuesday, October 28 from 9:00

a.m. - 11:00 a.m. in Hall A, Abstract: 1843

-- In vitro properties of CAM-3001, a human anti GM-CSF receptor antibody

for the treatment of patients with rheumatoid arthritis - Matthew

Sleeman, Ph.D., Tuesday, October 28 from 9:00 a.m. - 11:00 a.m. in Hall

A, Abstract: 1338

-- Use of a SOCS3 ex-vivopharmacodynamic quantitative RT-PCR assay for

CAM-3001, a new antibody therapy for the treatment of rheumatoid

arthritis - Jo Woods, Ph.D., Tuesday, October 28 from 9:00 a.m. - 11:00

a.m. in Hall A, Abstract: 1339

About MedImmune

MedImmune is a leading innovation-focused biotechnology company whose mission is to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on infection, oncology, respiratory disease and inflammation, cardiovascular/ gastrointestinal disease and neuroscience. Headquartered in Gaithersburg, Maryland, MedImmune has approximately 3,000 employees worldwide and is the wholly owned biologics business for AstraZeneca plc (LSE: AZN.L, NYSE: AZN). For more information, visit MedImmune's website at http://www.medimmune.com.


'/>"/>
SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
2. MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.
3. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
4. Pinnacle Biologics Announces Stock Purchase Agreement With MedImmune
5. MedImmunes Brian Rosen Honored by Montgomery County Chamber at 49th Annual Awards Dinner
6. Depth of MedImmunes Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society
7. MedImmune Fortifies Strategic Scientific Portfolio Management and International Leadership With New Executive Appointments
8. MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research
9. Seneca Valley High School Student Receives Science Award From MedImmune
10. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
11. MedImmune Submits Biologics License Application to FDA for Motavizumab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 2016  Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual ... of intellectual property, today provided an update on the ... District of Texas and announcing ... Inter Partes Re-examination ("IPR") proceedings that VTech and ... was initiated on only certain claims of two of ...
(Date:2/3/2016)... DIEGO , Feb. 3, 2016   ... company with the first pluripotent stem cell-derived islet ... diabetes in clinical-stage development, today announced that ViaCyte ... Pharmaceutical Companies of Johnson & Johnson, have agreed ... group into ViaCyte.  The agreement provides ViaCyte with ...
(Date:2/3/2016)... NEW BRUNSWICK, N.J. , Feb. 3, 2016 ... 30 grants totaling more than $1 million for ... who are working on health-related research that demonstrates ... , this round of funding for the New ... available for faculty members at these educational institutions— ...
(Date:2/3/2016)... Feb. 3, 2016  Silk Therapeutics, Inc., today announced the ... Therapeutics has now raised a total of $10.25 million in ... company. The Series A2 round was led by existing investor ... with participation from new investors Lear Corporation and Highland Consumer ... P. Disney ; Richard Sackler , MD, with Summer ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016  Based on ... Frost & Sullivan recognizes US-based Intelligent Retinal Imaging ... & Sullivan Award for New Product Innovation. IRIS, ... North America , is poised ... rapidly growing diabetic retinopathy market. The IRIS technology ...
(Date:2/1/2016)... 2016  Today, the first day of American Heart ... develop a first of its kind workplace health solution ... In the first application of Watson ... ), and Welltok will create a new offering that ... analytics, delivered on Welltok,s health optimization platform. The effort ...
(Date:1/28/2016)... SAN JOSE, Calif., Jan. 28, 2016 Synaptics (NASDAQ: ... financial results for its second quarter ended December 31, 2015. ... the second quarter of fiscal 2016 increased 2 percent compared to ... the second quarter of fiscal 2016 was $35.0 million, or $0.93 ... Non-GAAP net income for the first quarter of fiscal 2016 ...
Breaking Biology News(10 mins):